Please login to the form below
Exelixis
This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.
Merck’s Bavencio joins first-line kidney cancer face-off
Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’Cabometyx (cabozantinib) as the ... Exelixis’drug could also be
Latest news
-
Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?
EUROPE. European approval for Cabometyx in RCC. The European Commission has approved Ipsen and Exelixis’Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
-
Pfizer’s plans for Inlyta go awry with failed adjuvant trial
nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
-
FDA’s year-end approvals take annual tally to 46
The closing few days of 2017 also saw line extension approvals for Exelixis and Novartis. ... therapy. Analysts at Leerink have suggested the new indication could catapult Exelixis’cabozantinib franchise to $1bn in sales in 2025.
-
Ipsen’s liver cancer treatment clears phase III trial
Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half of next year, following positive phase III trial
-
Pfizer's SMO inhibitor boosts survival in blood cancer trial
Other SMO inhibitors are also coming through development meanwhile, notably Exelixis/Bristol-Myers Squibb's BMS 833923 - in phase II testing for CML - and Ignyta/ Eli Lilly's taladegib which is
More from news
Approximately 5 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Accelerating innovation
Meanwhile, 2016 saw a licensing deal with Cabometyx (cabozantinib) from Californian biotech Exelixis and an agreement with 3B Pharmaceuticals to develop novel oncology radiopharmaceuticals. ... It currently has a second-line licence in Europe, but Ipsen
-
Charting a course for expansion
Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
-
Deal Watch March 2016
Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Exelixis appoints Andrew Peters to newly created position
Exelixis appoints Andrew Peters to newly created position. He joins the biotech as its vice president, strategy. ... California, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy.
-
Decibel Therapeutics expands leadership team
Prior to this, he was president and chief executive of Exelixis and served as president of Bayer Biotechnology, overseeing the business development, manufacturing and R&D of the company's biological
-
Frances Heller joins BMS senior management
Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Medical Writers
-
Competitive Salary and Benefits
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Senior Account Executive, London, Medical Communications
-
Excellent package
- Events Manager – Med Comms – Surrey
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Director
-
£48, 000 - £60, 000
- Senior Systematic Review Analyst - Oxford
-
Negotiable
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
Subscribe to our email news alerts
- SPG Microstimulator System Market Value Share, Analysis and Segments 2017-2027
- Bionic Ears Market Revenue, Opportunity, Segment and Key Trends 2017-2027
- Endometriosis Treatment Market Growth, Forecast and Value Chain 2017-2027
- Transdermal Ultrasound Surgery Market Volume Analysis, size, share and Key Trends 2017-2027
- Steroid Releasing Implant Market Dynamics, Segments and Supply Demand 2017-2027
- Bioresorbable Coronary Scaffolds Market Analysis and Value Forecast Snapshot by End-use Industry 2017-2027
PMHub
GK Strategy
GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
